Oxford Biomedica PLC Block listing application (7435R)
September 25 2017 - 10:05AM
UK Regulatory
TIDMOXB
RNS Number : 7435R
Oxford Biomedica PLC
25 September 2017
Oxford BioMedica
Block listing Application
Oxford, UK - 25 September 2017: Oxford BioMedica plc ("OXB" or
"the Group") (LSE: OXB), a leading gene and cell therapy group,
announces that applications have been made to the Financial Conduct
Authority and the London Stock Exchange for admission to (i) the
Premium segment of the Official List and (ii) to trading on the
London Stock Exchange for a block listing of 35 million ordinary
shares of 1 pence each (the "Ordinary Shares").
The Ordinary Shares are being reserved under a block listing and
will be issued from time to time pursuant to the following
schemes:
-- 2007 and 2015 Employee Share Option Schemes (15 million Ordinary Shares); and
-- Long Term Incentive Plan (20 million Ordinary Shares).
It is expected that admission of the Ordinary Shares will become
effective on 28 September 2017. The Ordinary Shares will rank pari
passu in all respects with the Group's existing ordinary shares in
issue.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
280 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSZELFLDKFBBBF
(END) Dow Jones Newswires
September 25, 2017 10:05 ET (14:05 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024